Board approves final dividend at Rs. 5.00 for the F.Y. 2025-26
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts less than Nifty Microcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Ltd's Board meeting on May 12, 2026 resulted in three major outcomes. First, Mr. Amit Mahla was appointed as CEO effective immediately, succeeding Mr. Umesh Manohar Kunte who resigned on December 18, 2025. Mr. Mahla brings 28+ years of pharmaceutical experience from companies including Cipla, Sun Pharma, and JB Pharma. Second, the audited FY2026 results show a sharp decline in profitability with total income of Rs 34,105 Lacs (vs Rs 37,535 Lacs prior year) and a net loss of Rs 149 Lacs (vs profit of Rs 1,720 Lacs), attributed largely to negative other income of Rs 2,484 Lacs. Third, the Board recommended a final dividend of Rs 5 per share (50% on Rs 10 face value) for FY2026, subject to shareholder approval at the 87th AGM on August 6, 2026. Record date is July 30, 2026. PwC Services LLP and S. Gupta & Co. were reappointed as internal and cost auditors respectively for FY2027.
The appointment of a new CEO with strong pharma pedigree may provide stability following the December 2025 leadership gap, though the significant profit decline in FY2026 is a concern for shareholders. The dividend provides some investor relief despite weak financials.